Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: An observational study

Surgical Infections

Volumn 8, Issue 2, 2007, Pages 189-199

  Micek, Scott T ^a   Shah, Poorvi ^b   Hollands, James M ^a   Shah, Rina A ^a   Shannon, William D ^c   Kollef, Marin H ^c  

^a BARNES JEWISH HOSPITAL   (United States)

^b S Margaret Mercy Healthcare Centers   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; HYPERTENSIVE FACTOR; NORADRENALIN; VASOPRESSIN;

ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PATIENT CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY PERIOD; RESUSCITATION; RISK; RISK FACTOR; SEPTIC SHOCK; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; AGED; APACHE; DRUG COMBINATIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MISSOURI; NOREPINEPHRINE; ODDS RATIO; PROSPECTIVE STUDIES; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 34247261013     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.003     Document Type: Article

References (37)

1. Micek ST, Shah RA, Kollef MH. Management of severe sepsis: Integration of multiple pharmacologic interventions. Pharmacotherapy 2003;23:1486-1496.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence outcome and associated costs of care. Crit Care Med 2001;29:1303-1310.
3. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
4. Angus, DC, Wax RS. Epidemiology of sepsis: An update. Crit Care Med 2001;29(Suppl):S109-S116.
5. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
6. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-214.
7. Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-955.
8. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-595.
9. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
10. Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-2765.
11. Homes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
12. Rozenfeld V, Cheng JWM. The role of vasopressin in the treatment of vasodilation in shock states. Ann Pharmacother. 2000;34:250-254.
13. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003:31:1752-1758.
14. Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system 2: Clinical physiology. Crit Care 2004;8:15-23.
15. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
16. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.
17. Reid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation 1997;95:1108-1110.
18. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-493.
19. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001;27:1416-1421.
20. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock. Circulation 2003;107:2313-2319.
21. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582.
22. Orbritsch MD, Jung R, Fish DN, et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004;38:1117-1122.
23. Micek ST, Isakow W, Shannon WD, et al. Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated). Pharmacotherapy 2005;25:26-34.
24. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
25. Bone RC, Balk RA, Cerra FB, et al. ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
26. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
27. Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001;286:1754-1758.
28. Rosenbaum P. Observational Studies, Second edition. New York. Springer-Verlag, 2002.
29. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 2001;32:7-13.
30. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351:159-169.
31. Landry DW, Levin HR, Gallant EM, et al. Vasopressin hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282.
32. Mariscalo MM. More than skin deep? Complications associated with vasopressin infusion: A cautionary tale. Crit Care Med 2003;31:1587-1588.
33. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003;31:1394-1398.
34. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002;30:1899-1901.
35. van Haren FMP, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003;124:2256-2260.
36. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-2650.
37. Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33:2659-2666.